3061142-96-6
3061142-96-6
Chemical Structure
Evabosmig
Synonym(s): AGA2118
- CAS No.: 3061142-96-6
- Formula:N/A
- Molecular Weight:(145.18 kDa)
SMILES: [Evabosmig]
Biological Activity: Evabosmig (AGA2118) is a humanized bispecific monoclonal antibody targeting sclerostin (SOST/sclerostin) and DKK1. SOST and DKK1 are two key secreted negative regulators of the intramedullary Wnt/β-catenin pathway. Evabosmig possesses activities to induce bone formation, inhibit bone resorption and increase bone mineral density. Evabosmig is applicable for research related to osteoporosis[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Evabosmig | 97.91% | Evabosmig (AGA2118) is a humanized bispecific monoclonal antibody targeting sclerostin (SOST/sclerostin) and DKK1. SOST and DKK1 are two key secreted negative regulators of the intramedullary Wnt/β-catenin pathway. Evabosmig possesses activities to induce bone formation, inhibit bone resorption and increase bone mineral density. Evabosmig is applicable for research related to osteoporosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
-
[1]. Drake, M. T., et al. (2024, September). AGA2118, a bispecific monoclonal antibody neutralizing both sclerostin and DKK1, increased bone Formation, decreased bone resorption, and led to rapid BMD gains in a first in human, single-and multiple-dose, placebo-controlled, randomized study. In ASBMR 2024 Annual Meeting. ASBMR.
- [2]. Adami G, et al. Increase in serum DKK1 levels attenuates the anabolic response to romosozumab in postmenopausal osteoporosis. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2026 Feb 03;41(2):143-149.
